Skip to main content
Caplight Logo









Chimeron Bio

Chimeron Bio

Private
Philadelphia, PennsylvaniaHealthcare & Life Scienceshttps://www.chimeron.com/

Last Round

VC Round

Mar 2, 2025

Total Funding Raised

$1.68M

Company Overview

Chimeron Bio is a biotechnology company that develops self-amplifying RNA (saRNA) therapeutics and vaccines intended to treat diseases including cancer, infectious diseases, and genetic disorders.

Sector

Healthcare & Life Sciences

Verticals

Biotechnology, Drug Discovery, Clinical Trials, Precision Medicine

Business Model

B2B

Customer Profile

Government Contracts

AI Layer

Non-AI

Keywords

self-amplifying RNAsaRNAin-vivo CAR-TRNA therapeuticscancer vaccineimmuno-oncologyoff-the-shelf CAR-TmRNA 2.0gene deliverylarge payload deliverynanoparticle deliverypreclinical biotechnologyinfectious disease vaccinerare genetic disorders

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

Chimeron Bio Comparables

Compare Chimeron Bio with similar companies based on industry and business-model similarity.

Chimeron Bio comparables — related companies by embedding similarity
CompanySimilarityMarket Cap
Ziphius Vaccines
83%
Replicate Bioscience
83%
Kernalbio
83%

Chimeron Bio Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
VC RoundMar 2, 2025
GrantFeb 21, 2024
GrantJun 6, 2023
SeedFeb 28, 2022
GrantAug 28, 2020
Accelerator
Jun 1, 2017

Key People

Founding team and executive leadership

Kevin Heyeck

CEO and Director

Executive Team

Chimeron Bio Investors

Notable investors and investment history

Chimeron Bio investors
InvestorRounds
National Cancer InstituteGrant
Dreavent CapitalSeed
Alexandria Venture InvestmentsAccelerator

Market signals

Structured signals derived from secondary market and firmographic data.

  • May 2, 2025

    Monthly visitors increased 57% MoM.

  • Mar 2, 2025

    $14M raised in a VC Round.

Chimeron Bio Filings

Explore SEC and related filing metadata, where available.

Chimeron Bio filings preview — column headings only; records require access
TypeDateAmount OfferedAmount SoldFilingPagesDownload

Filing documents are not displayed on this public page. Request access to learn about available coverage.

Request access

Frequently Asked Questions

Common questions about Chimeron Bio's valuation, stock price, and market status.

Is Chimeron Bio a public or private company?

Chimeron Bio is a private company.

What is the current stock price of Chimeron Bio?

Chimeron Bio is a private company with no public stock price. No recent secondary market data is available.

How much is Chimeron Bio worth (valuation)?

Valuation information for Chimeron Bio is not publicly available.

Can I buy Chimeron Bio stock?

Chimeron Bio shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors. Visit https://www.caplight.com to learn more.

When was Chimeron Bio's last funding round?

Chimeron Bio's most recent funding round was VC Round on March 2, 2025.

Who are the main investors in Chimeron Bio?

Key investors in Chimeron Bio include National Cancer Institute, Dreavent Capital, Alexandria Venture Investments.

Will Chimeron Bio IPO soon?

No public IPO plans have been announced for Chimeron Bio.

How can I track Chimeron Bio secondary market activity?

Caplight tracks bids, offers, and trades for private companies. Visit https://www.caplight.com to monitor Chimeron Bio's secondary market activity and sign up for updates.

Firmographic Details

HeadquartersPhiladelphia, Pennsylvania
Employee Range11
Year Founded2015
Last FundingMar 2, 2025

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.

See something wrong or outdated?